An entrepreneurial and human adventure
More than 20 years of experience and continuous growth
<p><strong>[1998]</strong></p>
<p>Foundation of Provence Technologies, a <strong>research and development chemistry laboratory</strong>, resulting from the association of the 2 founding partners: Michel FERAUD and Christophe BARALOTTO. The company operates as a subcontractor for biotechnological companies and international pharmaceutical groups. The company thus builds its reputation in different fields such as pharmaceuticals, cosmetics and agrochemicals.</p>
<p><strong>[SINCE 2003]</strong></p>
<p>Given its solid financial structure, Provence Technologies launches several internal research programs. One of them concerns a new process for the synthesis of methylene blue, which led to <strong>the filing of a international patent in 2006.</strong> A year later, in 2007, Provepharm, a subsidiary of Provence Technologies, was founded to develop and commercialize this product.</p>
<p><strong>[2011]</strong></p>
<p><strong>Obtains a Centralized Marketing Authorization</strong> paving the way for the commercialization of Proveblue<sup>®</sup> in the 30 countries of the enlarged European Union: the authorities recognize patient benefit of Proveblue<sup>®</sup>.</p>
<p>Thus, Michel FERAUD, co-inventor with Babak SAYAH of this patent, also becomes President and builds a team of professionals as well as a committee of internationally renowned experts.</p>
<p><strong>[2014]</strong></p>
<p>The group acquires a company specialized in the<strong>chemical synthesis of peptides and proteins for therapeutic use.</strong> This operation opens a new development path for the company in the field of biological pharmaceutical products.</p>
<p><strong>[2016]</strong></p>
<p>An important milestone is reached: Provepharm <strong>obtains FDA approval </strong>to commercialize ProvayBlue<sup>™</sup>, its Injectable Methylene Blue.</p>
<p><strong>[2017]</strong></p>
<p>The company becomes <strong>Provepharm Life Solutions</strong> and launches its new brand identity. The adventure continues!</p>
<p><strong>[2018]</strong></p>
<p>Provepharm Life Solutions joins forces with <strong>new strategic partners</strong>, <a href="https://www.archimed.fr/" rel="noopener" target="_blank">A</a><a href="http://www.archimed-group.eu/" rel="noopener" target="_blank">rchiMed</a> et <a href="https://www.tethysinvestments.com/" rel="noopener" target="_blank">Téthys Invest</a>.</p>
<p><strong>[2019]</strong></p>
<p>Obtains a <strong>42.5 M€ syndicated loan.</strong></p>
<p><strong>Inauguration of the pilot plant</strong> located at Château Gombert, Marseille, head office.</p>
<p><strong>[2020]</strong></p>
<p>Provepharm Life Solutions acquires <strong>Apollo Pharmaceuticals USA</strong>, a company specialized in sterile injectable products with high added-value, to continue its growth in the United States. <a href="https://www.provepharm.com/en/news/provepharm-life-solutions-acquires-apollo-pharmaceuticals-usa">Read more.</a></p>
<p> </p>
<p><strong>[2021]</strong></p>
<p>Provepharm Life Solutions raises €120 million and enables the pharmaceutical group to reach a decisive milestone in the implementation of its Horizon 2025 strategic plan. <a href="https://www.provepharm.com/en/actualites/provepharm-life-solutions-raises-eu120-million">Read more.</a></p>
<p> </p>
<p>The company evolves its appearance and launches its new brand identity. This new graphic design brings together innovation, commitment and modernity, in line with our growth. <a href="https://www.provepharm.com/en/actualites/provepharm-life-solutions-revitalizes-its-identity-discover-it">Read more. </a></p>
<p><strong>[2022]</strong></p>
<p>Obtained a <strong>Marketing Authorization</strong> (MA) <strong>in France and the US</strong> for a new product: <strong>Provingo / Bludigo</strong>, indigo carmine solution for injection. <a href="https://www.provepharm.com/en/actualites/provepharm-receives-fda-marketing-approval-us-bludigo-its-indigo-carmine-injection-drug">Read more.</a></p>